Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting
Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…Abstract Number: 985 • 2016 ACR/ARHP Annual Meeting
Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool with or without a Health Educator for Knowledge of RA Risk Factors
Background/Purpose: Much progress has been made in identifying risk factors for RA, but it is unclear whether individuals at risk for RA have knowledge of…Abstract Number: 989 • 2016 ACR/ARHP Annual Meeting
A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study
Background/Purpose : Disclosure of genetic risk information alone has had limited impact on changing health behaviors in research trials. Prior studies have not evaluated whether…Abstract Number: 2589 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Measurement of plasma anti-TNF concentration, in combination with the assessment of clinical outcomes, may be used to optimize dosing regimens for individual patients (pts).…Abstract Number: 3014 • 2016 ACR/ARHP Annual Meeting
Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis
Background/Purpose: Treatment with biologicals is based on the principle of ‘one size fits all’ without taking differences into account for dosing schemes, patients’ characteristics and…Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…Abstract Number: 2619 • 2015 ACR/ARHP Annual Meeting
Clinical Usefulness of Periodic Detection of Serum 14-3-3η for Predicting Efficacy of Tocilizumab in RA
Background/Purpose: Serum 14-3-3η is a diagnostic marker for RA. Recent in vitro evidence indicates that it may play a casual role in the pathogenesis of…Abstract Number: 2008 • 2014 ACR/ARHP Annual Meeting
Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives
Background/Purpose Having a first-degree relative (FDR) with RA increases personal RA risk by four-fold. Other RA risk factors include demographics, genetics, auto-antibodies, and behaviors. We…Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…Abstract Number: 222 • 2014 ACR/ARHP Annual Meeting
OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA
Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing…Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting
Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…Abstract Number: 2666 • 2013 ACR/ARHP Annual Meeting
Implementing a Personalized Health Plan To Improve Therapeutic Outcomes In Veterans With Gout
Background: Gout is a chronic crystal-induced arthritis that predominantly occurs among men with rising prevalence with advancing age. Patients with uncontrolled gout present with recurrent…
ACR Meeting Abstracts